Bibliometric analysis reveals global thymoma research trends collaborations and emerging frontiers from 2010 to 2024
Thymoma research has evolved toward molecular and therapeutic innovation, emphasizing immunotherapy and precision medicine. Despite growth, geographical disparities and understudied areas (e.g., long-term outcomes) persist. Future efforts should prioritize multidisciplinary collaboration, biomarker discovery, and multicenter trials to optimize clinical strategies.
Authors
- Xintao Yu
- Xingguo Yang (ORCID: https://orcid.org/0000-0001-6883-4843)
- Jian Cui (ORCID: https://orcid.org/0000-0001-7677-9522)
- Yuhan Li (ORCID: https://orcid.org/0000-0002-7377-4889)
- Zhen Yu (ORCID: https://orcid.org/0000-0002-6357-5026)
- Xinpeng Wang (ORCID: https://orcid.org/0000-0002-0580-3895)
- Lei Yu
- Qi Han (ORCID: https://orcid.org/0000-0002-5856-383X)
- Xiang Gao (ORCID: https://orcid.org/0000-0002-8424-3602)
Institutions
- Beijing Tongren Hospital (CN)
- Fourth Affiliated Hospital of China Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1007/s12672-025-03732-4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Capital Medical University